Metastasizing Squamous Cell Carcinomas in a Patient Treated With Extracorporeal Photopheresis for Cutaneous T-cell Lymphoma

Regression of cutaneous invasive squamous cell carcinoma in a patient with chronic cutaneous graft versus host disease

“…Additionally, the continued growth of the SCC prior to initiation of ECP therapy with gradual regression after the start of photopheresis suggests that ECP may be inhibiting tumorigenesis. In contrast to our findings, our review of the literature revealed 4 cases of either multiple, aggressive and/or metastatic SCCs in patients with cutaneous T-cell lymphoma (CTCL) that were attributed to treatment with ECP [5][6][7]. However, tumor development was observed approximately 1-2 years [6,7], 2-5 years [7] , and 11 years [5] following ECP initiation.…”

“…In contrast to our findings, our review of the literature revealed 4 cases of either multiple, aggressive and/or metastatic SCCs in patients with cutaneous T-cell lymphoma (CTCL) that were attributed to treatment with ECP [5][6][7]. However, tumor development was observed approximately 1-2 years [6,7], 2-5 years [7] , and 11 years [5] following ECP initiation. Furthermore, 2 patients received two [7] and eleven [5] years of PUVA therapy, one patient had limited PUVA exposure (11.1 J/cm 2 ), and the last patient was treated with topical mechlorethamine [7]; both PUVA and mechlorethamine are associated with increased risk of skin cancer.…”

Cutaneous squamous cell carcinoma arising within a mycosis fungoides patch: Case report and review of the literature

“…1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 Development of SCCs in patients with MF on systemic therapy with INF-alpha, phototherapy (ultraviolet A, narrow-band ultraviolet B), and extracorporeal photopheresis has been previously reported. 3,4 In these reports, the authors suggested that the carcinogenic properties of ultraviolet irradiation could have contributed to the development of SCC in these patients. SCC development in an active, untreated MF lesion is even rarer.…”